Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
The ketogenic diet in children, adolescents and young adults with refractory epilepsy: an Italian multicentric experience
- G. Coppola, P. Veggiotti, R. Cusmai, S. Bertoli, A. Pascotto
- Medicine
- Epilepsy Research
- 1 February 2002
PURPOSE
This collaborative study by three Italian groups of child neuropsychiatrists was carried on to evaluate the efficacy and safety of the classic 4:1 ketogenic diet as add-on treatment in… Expand
Lamotrigine versus Valproic Acid as First‐line Monotherapy in Newly Diagnosed Typical Absence Seizures: An Open‐label, Randomized, Parallel‐group Study
- G. Coppola, G. Auricchio, R. Federico, M. Carotenuto, A. Pascotto
- Medicine
- Epilepsia
- 1 September 2004
Summary: Purpose: To compare the efficacy of lamotrigine (LTG) and valproic acid (VPA) in newly diagnosed children and adolescents with typical absence seizures.
Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): An open-label, parallel group trial
- G. Coppola, E. Franzoni, A. Verrotti, C. Garone, A. Pascotto
- Medicine
- Brain and Development
- 1 June 2007
To evaluate the efficacy and tolerability of levetiracetam or oxcarbazepine as monotherapy in children with newly diagnosed benign epilepsy with centrotemporal spikes (BECTS). Twenty-one children (11… Expand
Malignant migrating partial seizures in infancy: An epilepsy syndrome of unknown etiology
- G. Coppola
- Medicine
- Epilepsia
- 1 May 2009
The syndrome of malignant migrating partial seizures in infancy was first reported in 1995, and is now included among the childhood epilepsy syndromes in development in the proposal of the revision… Expand
Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications
- A. Verrotti, C. D'Egidio, A. Mohn, G. Coppola, F. Chiarelli
- Medicine
- Obesity reviews : an official journal of the…
- 1 May 2011
In the last years, a growing body of literature indicates an association between valproic acid therapy and weight gain. Weight gain during valproate treatment can be observed within the first 3… Expand
The metabolic syndrome in overweight epileptic patients treated with valproic acid
- A. Verrotti, Rossella Manco, S. Agostinelli, G. Coppola, F. Chiarelli
- Medicine
- Epilepsia
- 1 February 2010
Purpose: To evaluate the presence of metabolic syndrome (MS) in children and adolescents treated with valproate (VPA).
Efficacy and safety of levetiracetam: An add-on trial in children with refractory epilepsy
- S. Grosso, E. Franzoni, +9 authors P. Balestri
- Medicine
- Seizure
- 1 June 2005
The aim of this multicentric, prospective and uncontrolled study was to evaluate the efficacy and safety of levetiracetam in 110 children with refractory epilepsy, of whom 21 were less than 4 years… Expand
A multicenter, randomized, placebo‐controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy
- C. Fattore, C. Boniver, +7 authors E. Perucca
- Medicine
- Epilepsia
- 1 April 2011
Purpose: To evaluate the potential efficacy of levetiracetam as an antiabsence agent in children and adolescents with newly diagnosed childhood or juvenile absence epilepsy.
Neuropsychological impairment in children with Rolandic epilepsy and in their siblings
- A. Verrotti, S. Matricardi, Deborah Lidia Di Giacomo, D. Rapino, G. Coppola
- Psychology, Medicine
- Epilepsy & Behavior
- 1 July 2013
To assess and characterize a possible neurocognitive endophenotype associated with Rolandic epilepsy (RE), a clinical study was carried out to evaluate the neuropsychological profile of children with… Expand
Bone mineral density in a population of children and adolescents with cerebral palsy and mental retardation with or without epilepsy
- G. Coppola, D. Fortunato, +5 authors A. Verrotti
- Medicine
- Epilepsia
- 1 December 2012
Purpose: The present study aimed to assess bone mineral density (BMD) in a population of children and adolescents with cerebral palsy and mental retardation with or without epilepsy.